Review


DOI :10.26650/JARHS2020-S1-0007   IUP :10.26650/JARHS2020-S1-0007    Full Text (PDF)

COVID-19 and Coagulopathy

Ayşegül Ünüvar

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) is the causative pathogen of a new infectious disease, COVID-19. The lungs are the target organ for COVID-19; acute lung injury can progress to respiratory failure, and multiorgan failure can also occur. COVID-19 may predispose to both venous and arterial thromboembolic disease due to coagulation activation caused by a combination of excessive inflammation, platelet activation, endothelial dysfunction, and stasis in blood flow. This review was prepared in the light of the current information available in the first months of the COVID-19 pandemic. However, the existing evidence, including studies on thrombotic complications, is very limited and derived primarily from small and retrospective analyses, and more strong and high quality new studies are required.

DOI :10.26650/JARHS2020-S1-0007   IUP :10.26650/JARHS2020-S1-0007    Full Text (PDF)

COVID-19 ve Koagülopati

Ayşegül Ünüvar

Ağır Akut Solunum Sendromu Coronavirus 2’nin (SARS-CoV2) etken patojen olduğu SARS-CoV2 enfeksiyonu (COVID-19) yeni bir enfeksiyon hastalığıdır. Akciğerler COVID-19 için hedef organdır; akut akciğer hasarı solunum yetmezliğine ilerleyebilir ve çoklu organ yetersizliği de gelişebilir. COVID-19; inflamasyon artışı, trombosit aktivasyonu, endotel disfonksiyonu ve kan akımında stazın etkisiyle hem venöz hem de arteriyel sistemde tromboz gelişimine neden olabilir. Bu derleme, COVID-19 pandemisinin ilk aylarındaki mevcut güncel bilgiler ışığı altında hazırlandı. Ancak, trombotik komplikasyonla ilgili çalışmalar da dahil mevcut kanıtlar çok sınırlıdır, başlıca az sayıda hastaların olduğu retrospektif analizlere dayalıdır, daha güçlü ve yüksek kalitede yeni çalışmalara ihtiyaç vardır. 


PDF View

References

  • 1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020 Feb 15;395:497-506. doi: 10.1016/ S0140-6736(20)30183-5. google scholar
  • 2. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and thrombotic or thromboembolic disease: Implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol 2020 Apr 15. pii: S0735-1097(20)35008-7. doi: 10.1016/j.jacc.2020.04.031. google scholar
  • 3. Cannegieter SC, Klok FA. COVID-19 associated coagulopathy and thromboembolic disease: Commentary on an interim expert guidance. Res Pract Thromb Haemost 2020 April 20. doi:10.1002/rth2.12350. google scholar
  • 4. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020 Apr 27. pii: blood.2020006000. doi:10.1182/blood.2020006000. google scholar
  • 5. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 2020;46(4):586-590. doi: 10.1007/s00134020-05985-9. google scholar
  • 6. Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, Zhang Z. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost 2020 Apr 19. doi: 10.1111/ jth.14859. google scholar
  • 7. Ranucci M, Ballotta A, Di Dedda U, Bayshnikova E, Dei Poli M, Resta M, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost 2020 Apr 17. doi: 10.1111/jth.14854. google scholar
  • 8. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020 Mar28;395(10229):1054-1062. doi: 10.1016/ S0140-6736(20)30566-3. google scholar
  • 9. Thachil J, Tang N, Gando S, Falanga A, Levi M, Clark C, Iba T. Laboratory haemostasis monitoring in COVID-19. J Thromb Haemost 2020 Apr 23. doi: 10.1111/jth.14866. google scholar
  • 10. Thachil J. What do monitoring platelet counts in COVID-19 teach us? J Thromb Haemost 2020 Apr 28. doi: 10.1111/jth.14879. google scholar
  • 11. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020;18(5):1023-1026. doi: 10.1111/jth.14810. Epub 2020 Apr 27. google scholar
  • 12. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020 Apr;18(4):844-847. doi: 10.1111/jth.14768. Epub 2020 Mar 13. google scholar
  • 13. Han H, Yang L, Liu R, Liu F, Wu KL, Li J, Liu XH and Zhu CL. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med 2020 Mar 16. pii: /j/cclm.ahead-of-print/cclm-2020-0188/cclm2020-0188.xml. doi: 10.1515/cclm-2020-0188. google scholar
  • 14. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and antiphospholipid antibodies in patients with COVID-19. N Engl J Med 2020 Apr 23;382(17):e38. doi: 10.1056/ NEJMc2007575. Epub 2020 Apr 8. google scholar
  • 15. Harzallah I, Debliquis A, Drénou B. Lupus anticoagulant is frequent in patients with Covid-19. J Thromb Haemost 2020 Apr 23. doi: 10.1111/jth.14867. [Epub ahead of print] google scholar
  • 16. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 2020 Apr 9. doi: 10.1111/jth.14830 google scholar
  • 17. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020 pii: S0049-3848(20)30120-1. doi:10.1016/j.thromres.2020.04.013. google scholar
  • 18. Helms J, Tacquard, Severac F, Leonard-Lorant I, Ohana M, Delabranche X et al. for the CRICS TRIGGERSEP Group. High risk of thrombosis in patients in severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intens Care Med 2020: DOI: 10.1007/s00134-020-06062-x google scholar
  • 19. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected. Interim guidance 28 January 2020. Accessible at: https://www.who. int/docs/default-source/coronaviruse/clinicalmanagement-of-novel-cov.pdf. google scholar
  • 20. Tang N, Bai H, Chen X, Gong J, Li D and Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020 May;18(5):1094-1099. doi: 10.1111/jth.14817. Epub 2020 Apr 27. google scholar
  • 21. Llitjos JF, Leclerc M, Chochois C, Monsallier JM, Ramakers M, Auvray M, Merouani K. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost 2020 Apr 22. doi: 10.1111/ jth.14869. google scholar
  • 22. Thachil J, Tang N, Gando S, Falanga A, Levi M, Clark C, et al. Type and dose of heparin in COVID-19. J Thromb Haemost 2020 Apr 23. doi: 10.1111/jth.14870. google scholar
  • 23. Thachil J. The versatile heparin in COVID-19. J Thromb Haemost 2020 May;18(5):1020-1022. doi: 10.1111/jth.14821. Epub 2020 Apr 27. google scholar
  • 24. Belen-Apak FB, Sarialioglu F. The old but new: Can unfractioned heparin and low molecular weight heparins inhibit proteolytic activation and cellular internalization of SARS-CoV2 by inhibition of host cell proteases? Med Hypotheses 2020 Apr 20;142:109743. doi: 10.1016/j.mehy.2020.109743. google scholar
  • 25. T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü: COVID-19 (SARS-CoV-2 Enfeksiyonu) Rehberi. Bilim Kurulu Çalışması, T. C. Sağlık Bakanlığı 14 Nisan 2020, Ankara. google scholar
  • 26. Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, et al. Acute Myocardial Infarction after LaboratoryConfirmed Influenza Infection. N Engl J Med 2018;378:345- 353. google scholar
  • 27. Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res 2020 Apr 23;191:9-14. doi: 10.1016/j.thromres.2020.04.024. google scholar
  • 28. McGonagle D, O’Donnell JS, Sharif K, Emery P, Bridgewood C. Immune mechanisms of pulmonary intravascular coagulopathy (PIC) in COVID-19 pneumonia. Lancet Rheumatology 2020 (In Press). ISSN 2665-9913. google scholar
  • 29. Fox SE, Akmatbekov A, Harbert JL, Li G, Brown QJ, Vander Heide RS. Pulmonary and cardiac pathology in Covid-19: The first autopsy series from New Orleans. MedRxiv 2020. doi: https:// doi.org/10.1101/2020.04.06.20050575. google scholar
  • 30. Tian S, Hu W, Niu L, Liu H, Xu H, Xiao SY. Pulmonary pathology of early-phase 2019 novel Coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol 2020 May;15(5):700-704. doi: 10.1016/j. jtho.2020.02.010. google scholar
  • 31. Barrett C, Moore HB, Moore EE, McIntyre RC, Moore PK, Burke J, et al. Fibrinolytic therapy for refractory COVID‐19 Acute Respiratory Distress Syndrome: Scientific rationale and review. Res Pract Thromb Haemost 2020 April 28. doi:10.1002/rth2.12357. google scholar
  • 32. Whyte, Morrow GB, Mitchell JL, Chowdary P, Mutch NJ. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19. J Thromb Haemost 2020 Apr 23. doi: 10.1111/jth.14872. google scholar
  • 33. Asakura H, Ogawa H. Potential of heparin and nafamostat combination therapy for COVID‐19. J Thromb Haemost 2020 April 17. doi:10.1111/ jth.14858. google scholar
  • 34. Shatzel JJ, DeLoughery EP, Lorentz CU, Tucker EI, Aslan JE, Hinds MT, et al. The contact activation system as a potential therapeutic target in patients with COVID‐19. Res Pract Thromb Haemost 2020 April 18. doi:10.1002/ rth2.12349. google scholar
  • 35. Liu J, Li J, Arnold K, Pawlinski R, Key NS. Using heparin molecules to manage COVID-2019. Res Pract Thromb Haemost 2020 April 23. doi:10.1002/rth2.12353. google scholar

Citations

Copy and paste a formatted citation or use one of the options to export in your chosen format


EXPORT



APA

Ünüvar, A. (2020). COVID-19 and Coagulopathy. Journal of Advanced Research in Health Sciences, 3(1), 53-62. https://doi.org/10.26650/JARHS2020-S1-0007


AMA

Ünüvar A. COVID-19 and Coagulopathy. Journal of Advanced Research in Health Sciences. 2020;3(1):53-62. https://doi.org/10.26650/JARHS2020-S1-0007


ABNT

Ünüvar, A. COVID-19 and Coagulopathy. Journal of Advanced Research in Health Sciences, [Publisher Location], v. 3, n. 1, p. 53-62, 2020.


Chicago: Author-Date Style

Ünüvar, Ayşegül,. 2020. “COVID-19 and Coagulopathy.” Journal of Advanced Research in Health Sciences 3, no. 1: 53-62. https://doi.org/10.26650/JARHS2020-S1-0007


Chicago: Humanities Style

Ünüvar, Ayşegül,. COVID-19 and Coagulopathy.” Journal of Advanced Research in Health Sciences 3, no. 1 (May. 2022): 53-62. https://doi.org/10.26650/JARHS2020-S1-0007


Harvard: Australian Style

Ünüvar, A 2020, 'COVID-19 and Coagulopathy', Journal of Advanced Research in Health Sciences, vol. 3, no. 1, pp. 53-62, viewed 26 May. 2022, https://doi.org/10.26650/JARHS2020-S1-0007


Harvard: Author-Date Style

Ünüvar, A. (2020) ‘COVID-19 and Coagulopathy’, Journal of Advanced Research in Health Sciences, 3(1), pp. 53-62. https://doi.org/10.26650/JARHS2020-S1-0007 (26 May. 2022).


MLA

Ünüvar, Ayşegül,. COVID-19 and Coagulopathy.” Journal of Advanced Research in Health Sciences, vol. 3, no. 1, 2020, pp. 53-62. [Database Container], https://doi.org/10.26650/JARHS2020-S1-0007


Vancouver

Ünüvar A. COVID-19 and Coagulopathy. Journal of Advanced Research in Health Sciences [Internet]. 26 May. 2022 [cited 26 May. 2022];3(1):53-62. Available from: https://doi.org/10.26650/JARHS2020-S1-0007 doi: 10.26650/JARHS2020-S1-0007


ISNAD

Ünüvar, Ayşegül. COVID-19 and Coagulopathy”. Journal of Advanced Research in Health Sciences 3/1 (May. 2022): 53-62. https://doi.org/10.26650/JARHS2020-S1-0007



TIMELINE


Submitted24.04.2020
Accepted04.05.2020
Published Online15.05.2020

LICENCE


Attribution-NonCommercial (CC BY-NC)

This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.


SHARE




Istanbul University Press aims to contribute to the dissemination of ever growing scientific knowledge through publication of high quality scientific journals and books in accordance with the international publishing standards and ethics. Istanbul University Press follows an open access, non-commercial, scholarly publishing.